Expanding Territory into the Early-Stage Non-Small Cell Lung Cancer Market

Johnson & Johnson (JNJ) has officially launched the 'AmiNA' Phase 2 clinical trial (NCT07586202) targeting patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), expanding its treatment area into earlier stages of the disease. This trial focuses on patients in stages II to IIIB who are eligible for surgery and is designed as a neoadjuvant therapy to reduce tumor size before surgery, moving beyond the conventional treatment approach centered on patients with advanced, metastatic disease. The trial evaluates the combination of amivantamab (Rybrevant), an EGFR-MET bispecific antibody, with lazertinib (Leclaza/Lazcluze), a third-generation EGFR targeted therapy, or platinum-based chemotherapy (carboplatin + pemetrexed) to assess its efficacy. J&J aims to verify whether the successful combination of amivantamab and lazertinib, already approved as a first-line treatment for stage IV metastatic NSCLC, will also be effective as a neoadjuvant therapy.

Scientific Synergy and Clinical Value of Combination Therapy

The core of neoadjuvant therapy is to significantly reduce tumor size before surgery, maximizing the possibility of complete resection (R0 Resection) and early elimination of micrometastases to reduce recurrence rates. Amivantamab simultaneously blocks EGFR and MET receptors, inhibiting cancer cell growth and activating immune cell induction, while lazertinib strongly inhibits intracellular signaling pathways, demonstrating excellent synergy. If this targeted dual combination therapy proves to have a higher major pathological response (MPR) compared to conventional platinum-based chemotherapy, patients will be able to receive a safer treatment option instead of highly toxic chemotherapy. This will not only improve the long-term survival rate of patients but also significantly improve the quality of life for early-stage lung cancer patients, marking a significant clinical milestone.

Partnership with Yuhan Corporation and Commercial Milestones

Lazertinib, one of the key drugs in this trial, is a substance licensed from Yuhan Corporation, highlighting the strategic partnership between the two companies. The two companies signed a global licensing agreement in 2018 with a total value of $1.25 billion (including a $50 million upfront payment), and achieved cumulative milestones of $300 million, including the achievement of the European commercialization milestone in May 2026. J&J plans to maximize the synergy of co-selling its blockbuster drug, amivantamab, based on its global commercialization rights, and significantly strengthen the profitability of its lung cancer portfolio. The success of this partnership will directly affect the market penetration speed of the amivantamab-lazertinib combination and the expansion of additional indications.

Competition with AstraZeneca's Tagrisso

Currently, AstraZeneca (AZN) holds a dominant position in the EGFR-mutated NSCLC market with its third-generation TKI treatment, Tagrisso (Osimertinib), making intense competition inevitable. AstraZeneca is already actively verifying the efficacy of Tagrisso alone or in combination with chemotherapy through the Phase 3 'NeoADAURA' trial in the neoadjuvant therapy area, making it crucial for J&J to gain a first-mover advantage in the market. Given that the EGFR-mutated NSCLC treatment market is expected to grow from approximately $16.1 billion in 2026 to $39.2 billion in 2036, gaining an advantage in the early-stage market will be a key factor in determining long-term revenue growth. If J&J's combination therapy demonstrates superior clinical data compared to Tagrisso, it will create a decisive opportunity to reshape the global lung cancer treatment paradigm around its own approach.